Cure First Cancer Think Tank 2.0 was a success. The Seattle conference tackles the future of functional precision oncology.
An important read about the foundation and future of functional precision medicine to help current cancer patients and the oncologists who treat them. As told by SEngine Precision Medicine CEO Carla Grandori, MD. Ph.D.
Personalized Oncology Screening Results Validated in Method Developed by Seattle Cancer Research Organizations. Click here to read the paper in Cancer Discovery (PMID_28331002).
SEngine Precision Medicine Signs New Licensing Agreement with Fred Hutchinson Cancer Research Center
Nature Medicine cites SEngine collaborative work with Cornell Institute for Precision Medicine. July 2017 23(7) 796-799, (PMID_28697178)
A Road Map for Precision Cancer Medicine Using Personalized Models. Cancer Discovery May 2017 PMID_28461408
There are hundreds of drugs that treat cancer, and every patient reacts differently to each of them. That means doctors are often left in the dark when choosing which treatment to give a patient and patients often don’t get the most effective treatment for them.
Former Fred Hutch Tech Transfer V.P. Joins Seattle Cancer-Fighting Startup SEngine Precision Medicine as Chief Business Officer